BIOXYTRAN, INC 1Q 2026: Net loss $(2.07M), EPS $(0.02) — 10-Q SummaryTradingView·May 15 at 12:31 PMBIXT+9.17%
NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization | NRXBF Stock NewsStockTitan·Apr 7 at 12:20 AMABCL+0.35%XBI-2.94%
Bioxytran Raises Capital to Advance Development and CommercializationTip Ranks·Mar 20 at 08:33 AMBIXT+9.17%
BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT | BIXT Stock NewsStockTitan·Mar 20 at 12:05 AMBIXT+9.17%
Bioxytran Reports Positive Dose Optimization Results, Advances ProLectin-M Toward Phase 3 Trialrttnews·Mar 5 at 01:00 AMBIXT+9.17%
Bioxytran sees positive dose optimization, moves to Phase 3 trial for ProLectin-M with 408 patients, targeting viral infected outpatients.Unusual Whales·Mar 4 at 02:42 PMBIXT+9.17%
Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M | BIXT Stock NewsStockTitan·Mar 4 at 06:40 AMBIXT+9.17%
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19 | BIXT Stock NewsStockTitan·Mar 2 at 02:40 AMBIXT+9.17%
